vs
Ardmore Shipping Corp（ASC）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Ardmore Shipping Corp的季度营收约是MESA LABORATORIES INC的1.2倍（$81.2M vs $65.1M），Ardmore Shipping Corp净利率更高（15.7% vs 5.6%，领先10.2%），MESA LABORATORIES INC同比增速更快（3.6% vs -15.5%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -6.0%）
阿德莫尔航运是一家全球化海上运输企业，持有并运营中型成品油轮与化学品运输船队，可为全球能源、化工及贸易领域客户提供石油产品、特种化学品及其他散装液态货物的海运服务。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ASC vs MLAB — 直观对比
营收规模更大
ASC
是对方的1.2倍
$65.1M
营收增速更快
MLAB
高出19.1%
-15.5%
净利率更高
ASC
高出10.2%
5.6%
两年增速更快
MLAB
近两年复合增速
-6.0%
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $81.2M | $65.1M |
| 净利润 | $12.8M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 16.1% | 12.2% |
| 净利率 | 15.7% | 5.6% |
| 营收同比 | -15.5% | 3.6% |
| 净利润同比 | -47.0% | 316.6% |
| 每股收益（稀释后） | $0.30 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASCMLAB
| Q4 25 | — | $65.1M | ||
| Q3 25 | $81.2M | $60.7M | ||
| Q2 25 | $72.0M | $59.5M | ||
| Q1 25 | $74.0M | $62.1M | ||
| Q4 24 | — | $62.8M | ||
| Q3 24 | $96.1M | $57.8M | ||
| Q2 24 | $121.3M | $58.2M | ||
| Q1 24 | $106.3M | $58.9M |
净利润ASCMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $12.8M | $2.5M | ||
| Q2 25 | $9.6M | $4.7M | ||
| Q1 25 | $6.3M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $24.1M | $3.4M | ||
| Q2 24 | $62.7M | $3.4M | ||
| Q1 24 | $39.2M | $-254.6M |
毛利率ASCMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率ASCMLAB
| Q4 25 | — | 12.2% | ||
| Q3 25 | 16.1% | 7.8% | ||
| Q2 25 | 13.5% | 5.1% | ||
| Q1 25 | 8.6% | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | 25.4% | 6.1% | ||
| Q2 24 | 51.3% | 9.6% | ||
| Q1 24 | 37.2% | -460.6% |
净利率ASCMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | 15.7% | 4.1% | ||
| Q2 25 | 13.3% | 8.0% | ||
| Q1 25 | 8.5% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 25.1% | 5.9% | ||
| Q2 24 | 51.7% | 5.8% | ||
| Q1 24 | 36.9% | -432.2% |
每股收益（稀释后）ASCMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | $0.30 | $0.45 | ||
| Q2 25 | $0.22 | $0.85 | ||
| Q1 25 | $0.14 | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $0.55 | $0.63 | ||
| Q2 24 | $1.47 | $0.62 | ||
| Q1 24 | $0.92 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.0M |
| 总债务越低越好 | $116.1M | $68.4M |
| 股东权益账面价值 | $628.2M | $186.7M |
| 总资产 | $799.8M | $434.8M |
| 负债/权益比越低杠杆越低 | 0.18× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ASCMLAB
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务ASCMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | $116.1M | $69.4M | ||
| Q2 25 | $25.0M | $70.3M | ||
| Q1 25 | $20.5M | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | $22.5M | $73.1M | ||
| Q2 24 | $44.2M | $74.1M | ||
| Q1 24 | $23.1M | — |
股东权益ASCMLAB
| Q4 25 | — | $186.7M | ||
| Q3 25 | $628.2M | $178.5M | ||
| Q2 25 | $618.3M | $172.5M | ||
| Q1 25 | $610.7M | $159.8M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | $627.0M | $161.5M | ||
| Q2 24 | $617.7M | $150.7M | ||
| Q1 24 | $567.9M | $145.4M |
总资产ASCMLAB
| Q4 25 | — | $434.8M | ||
| Q3 25 | $799.8M | $430.4M | ||
| Q2 25 | $703.8M | $435.7M | ||
| Q1 25 | $690.4M | $433.3M | ||
| Q4 24 | — | $433.3M | ||
| Q3 24 | $722.8M | $454.1M | ||
| Q2 24 | $742.0M | $440.4M | ||
| Q1 24 | $704.1M | $446.8M |
负债/权益比ASCMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | 0.18× | 0.39× | ||
| Q2 25 | 0.04× | 0.41× | ||
| Q1 25 | 0.03× | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | 0.04× | 0.45× | ||
| Q2 24 | 0.07× | 0.49× | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 1.40× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流ASCMLAB
| Q4 25 | — | $18.8M | ||
| Q3 25 | $17.9M | $8.2M | ||
| Q2 25 | $11.2M | $1.9M | ||
| Q1 25 | $26.3M | $12.7M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | $39.9M | $5.3M | ||
| Q2 24 | $48.4M | $10.7M | ||
| Q1 24 | $49.2M | $12.9M |
自由现金流ASCMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率ASCMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度ASCMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率ASCMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 1.40× | 3.32× | ||
| Q2 25 | 1.17× | 0.40× | ||
| Q1 25 | 4.20× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.65× | 1.54× | ||
| Q2 24 | 0.77× | 3.17× | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASC
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
